Anti-EGFR activity leads to NK cell activation and subsequent lytic activity on tumor cells by antibody-dependent cellular cytotoxicity, Treg immunosuppression and induces PD-L1 expression on tumor cells via INFγ (87–89). Here, EGFR is linked to neoplasm.